Skip to main content

ACPA – Alberta Cosmetic

By Dr. Kamal Alhallak, PhD | Part 2 of 10

I look back on the beginning of this case through the Court of Appeal's December 19, 2025 judgment. The Court rejected the reasoning that a service necessarily falls outside pharmacy practice because it is provided for a cosmetic purpose. It also sent professional-services issues back for reconsideration. That distinction matters: the judgment clarified the legal framework while leaving particular compliance questions to be addressed through the remitted process. [1]

Against that background, I want to explain an important part of my journey with the Alberta College of Pharmacy: I had asked for guidance before the complaints, and I later asked the registrar for a framework. Those requests belong in the account of how this dispute developed.

My first question about cosmetic Botox came in 2016

The 2022 Hearing Tribunal decision records my testimony about an exchange with Jennifer Mosher in December 2016, when she was an ACP practice consultant. I asked about the College's position on pharmacists administering cosmetic Botox. According to that account, her response emphasized the pharmacist's responsibility to have appropriate training, assessment skills, and the ability to handle emergencies. I acknowledged in my reply that cosmetic Botox remained a grey area. [2]

That exchange is significant because it shows that I was asking about professional expectations before the later inspection and formal complaints. My question concerned how to practise responsibly in an area where I believed pharmacists could contribute. I was trying to understand the relationship between my existing professional authorizations, additional training, and the services I wanted to provide.

I do not describe that reply as an unrestricted approval of everything that followed. Its emphasis was on competence and responsibility. My view is that this was also an opportunity for a more developed conversation about what competence would mean in practice, how it should be demonstrated, and what expectations should apply in a cosmetic setting.

Why general guidance left important questions open

A statement that a pharmacist must be appropriately trained is important, but a practitioner still needs to understand how that expectation applies to a particular service. What assessment is required? How should treatment decisions be recorded? What communication is expected with other health professionals? How should the clinic's activities relate to the operations of a licensed pharmacy?

These are the kinds of questions that later became central to my proceedings. The Court's judgment identifies disputes about obtaining and administering Botox, assessment, documentation, collaboration, and storage. The distinction between a cosmetic purpose and professional obligations therefore had practical consequences throughout the case. [1]

My own understanding and arguments also developed during this process. In earlier testimony, I took a narrower view of ACP's authority over the medical spa. The Court subsequently clarified that the relevant professional activities fell within pharmacy practice even when performed for appearance-related purposes. I read the earlier exchanges in light of that clarification, rather than presenting every position I advanced at the time as having been accepted. [1] [2]

The June 20, 2019 request that went unanswered

The clearest record of my request for a broader framework appears in paragraph 12 of ACP's February 2024 Appeal Panel decision. It records that, on June 20, 2019, I wrote to the registrar asking the College to recognize pharmacists' role in cosmetic medicine and regulate that area within its practice standards. I also asked for communication with the College of Physicians and Surgeons of Alberta, the nursing regulator then known as CARNA, and Alberta Health to organize and standardize the medical spa industry. [3]

The same paragraph records that I did not receive a response to that letter. This is an important documented fact for me. The request was made before the registrar's formal complaint of September 3, 2019, although the inspection process was already underway. [3]

I wanted the expertise and experience of pharmacists working in the field to contribute to clear expectations. I believed a discussion among the relevant regulators could address areas of overlap and uncertainty. The fact that I disagreed with aspects of the inspection did not prevent me from asking the College to help build that framework.

I also asked for an opportunity to discuss my concerns

The Tribunal records my testimony that I requested a meeting with the registrar through his assistant after the Westwood Pharmacy inspection in March 2019. I later wrote to the College's president because I felt unfairly treated and wanted a meeting. According to the recorded testimony, the president replied that it would be inappropriate for a Council member to meet while the inspection was underway. [4]

I can understand why an institution would be concerned about maintaining the integrity of an ongoing process. From my position, however, that left an unresolved question: where could I raise concerns about the way the process itself was unfolding and have them considered?

The unsuccessful meeting requests and the unanswered framework letter contributed to my sense that the available conversation was becoming narrower. The concerns about my practice were being pursued through inspection and discipline, while my request for a structured discussion about the field did not receive the response I had hoped for. That is my experience of those events.

What the Court's later decision changes in this account

The Court's reasoning is important to my request for a framework. It recognized that the College has responsibilities to provide direction, regulate practice, and establish and enforce standards. It also rejected a categorical division that excluded an otherwise relevant activity from pharmacy practice simply because its purpose was cosmetic. [1]

At the same time, the Court did not decide that my request for guidance relieved me of professional obligations. Nor did it approve every aspect of my practice. My position is that clear guidance and professional accountability should develop together, especially when the boundaries of an area of practice are disputed.

The human context also matters. The Court recognized that I felt singled out and that I believed my work and qualifications were being disregarded. It upheld the reversal of the findings concerning my response to the investigation, while also stating that there was no evidence of improper motives by College officers. That is the basis on which I describe both my frustration and the limits of what was decided. [1]

The conversation I still believe was worth having

I cannot know whether an earlier substantive response would have prevented the hearing or resolved the disagreements. I can say that a request for collaboration was made and that the Appeal Panel recorded it as unanswered.

For me, the practical lesson is that a regulator's response to an emerging area should include a clear route for discussing training, competence, documentation, and professional responsibilities. Practitioners should be able to bring their experience to that discussion. The June 2019 letter remains part of why I believe there was an opportunity for a more constructive exchange before this dispute became so extensive.

Sources and documents

[1] Court of Appeal judgment, Al-Hallak v Alberta College of Pharmacy, 2025 ABCA 419. Paragraphs 19, 28, 33–57, 135–144, 147–152. Read the Court of Appeal judgment.

[2] 2022 Hearing Tribunal merits decision. Paragraphs 193 and 196, PDF page 46.

[3] 2024 Appeal Panel merits decision. Paragraphs 11–14, PDF pages 3–4; paragraph 12 on PDF page 4.

[4] 2022 Hearing Tribunal merits decision: requests for meetings. Paragraphs 201–202, PDF pages 47.

Start the series: My ACP journey